All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort studyMichael Manns, Stephanie Noviello, S. Pol et al.|The Lancet|2014Cited by 343
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19Roberto Caricchio, Samuel L. Krachman, Sarah Whelan et al.|JAMA|2021Cited by 166
All‐oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub‐analysis in Asian patients from the <scp>HALLMARK DUAL</scp> studyJia‐Horng Kao, Stephanie Noviello, Youn‐Jae Lee et al.|Liver International|2016Cited by 28
Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimensK. Rajender Reddy, Stephanie Noviello, Stanislas Pol et al.|Liver International|2017Cited by 24
O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTSM.P. Manns, Stephanie Noviello, S. Pol et al.|Journal of Hepatology|2014Cited by 20